Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers

NEXT STORY
I-Mab Filed 2019 Annual Report on Form 20-F
PREV STORY
Telehealth Market by Component Software & Services, Application, Hardware, End-User & Delivery Mode – Trends & Global Forecast to 2025
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Surya Psychiatric Clinic Brings Revolutionary FDA-Cleared Mental Health Technology for Major Depressive Disorder (MDD) to Patients in Arizona

author_avatar
NASDAQ Market News

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

author_avatar
NASDAQ Market News

Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress

author_avatar
NASDAQ Market News